Identyfikacja ekspresji liganda CD40 (CD154) na powierzchni konglomeratu płytka-monocyt u dzieci z zespołem metabolicznym

Urban, Mirosława; Urban, Remigiusz; Krasowska, Irena; Głowińska-Olszewska, Barbara; Stasiak-Barmuta, Anna; Bossowski, Artur; Koput, Alicja
June 2008
Pediatric Endocrinology, Diabetes & Metabolism;2008, Vol. 14 Issue 2, p71
Academic Journal
Introduction: The increased expression of the transmembrane protein CD40 on macrophages, endothelium, smooth muscle cells, platelet-monocyte conglomerate is connected with an enlarged risk of the occurrence of diseases of the cardiovascular system in the metabolic syndrome. The aim of the study was to establish whether metabolic syndrome in children can already be a precursor of cardiovascular diseases. Material and methods: The study was carried out on 35 children aged 10-18 years with the metabolic syndrome recognized according to the National Cholesterol Educational Program Adult Treatment Panel III (ATP III) criteria. The control group consisted of 26 healthy children without risk factors. In the examined children we evaluated BMI, the blood pressure, lipids, hsCRP, and the HOMA index. The analysis of the expression CD 40L (CD154) was performed with a three-color flow cytometer. The identification surrendered 104 cells. Statistical analysis was performed with use of U-Mann-Whitney test, for correlation analysis we used Spearman and Pearson tests. Results: We observed an elevated expression of CD40 ligand on the surface on platelet-monocyte conglomerate in patients with the metabolic syndrome compared to healthy children (12.7 vs. 4.95%, p=0.0036). In addition, we found a statistically significant correlation between the expression of the CD40L and HOMA index (r = -0.33, p<0.028). Conclusions: Enlarged expression of the transmembrane protein CD40L not only initiates and influences the progression of the atherosclerosis, but modulates the architecture of atherosclerotic plaque as well.


Related Articles

  • In stent restenosis: bane of the stent era. Mitra, A. K.; Agrawal, D. K. // Journal of Clinical Pathology;Mar2006, Vol. 59 Issue 3, p232 

    The long term outcome of stent implantation is affected by a process called in stent restenosis (ISR). Multiple contributory factors have been identified, but clear understanding of the overall underlying mechanism remains an enigma. ISR progresses through several different phases and involves...

  • Platelet Resistance to the Anti-Aggregating Agents in the Insulin Resistant States. Anfossi, Giovanni; Russo, Isabella; Trovati, Mariella // Current Diabetes Reviews;2006, Vol. 2 Issue 4, p409 

    Insulin resistance is a relevant risk factor for the major cardiovascular events, caused by severe atherosclerotic involvement of coronary, cerebral and lower limb blood vessels. One of the alterations accounting for this increased cardiovascular risk is the impairment of platelet function,...

  • Adiponectin Increases Fatty Acid Oxidation in Skeletal Muscle Cells by Sequential Activation of AMP-Activated Protein Kinase, p38 Mitogen-Activated Protein Kinase, and Peroxisome Proliferator-Activated Receptor α. Myeong Jin Yoon; Gha Young Lee; Jun-Jae Chung; Young Ho Ahn; Seung Hwan Hong; Jae Bum Kim // Diabetes;Sep2006, Vol. 55 Issue 9, p2562 

    Adiponectin has recently received a great deal of attention due to its beneficial effects on insulin resistance and metabolic disorders. One of the mechanisms through which adiponectin exerts such effects involves an increase in fatty acid oxidation in muscle and liver. In the present study, we...

  • Testosteron ve kardiyovasküler risk. Arpacı, Dilek; Ersoy, Reyhan // Journal of Dialog in Endocrinology / Endokrinolide Diyalog Dergi;Dec2011, Vol. 8 Issue 4, p177 

    The effects of androgens on cardiovascular pathophysiology have not yet been completely clarified. It is known that many components of the metabolic syndrome such as obesity, dyslipidemia, diabetes mellitus and insulin resistance can be observed in hypogonadal men. These components are related...

  • Metabolic Syndrome. Reynolds, Kristi; Muntner, Paul; Fonseca, Vivian // Diabetes Care;Jul2005, Vol. 28 Issue 7, p1831 

    Discusses issues concerning the metabolic syndrome, a cluster of cardiovascular risk factors frequently associated with insulin resistance. Lack of records on the syndrome; Concern that reimbursement will not be provided if the metabolic syndrome is listed as an ICD-9 code; Establishment of the...

  • Metabolic Syndrome in Rheumatoid Arthritis. Cojocaru, Manole; Cojocaru, Inimioara Mihaela; Silosi, Isabela; Vrabie, Camelia Doina // Maedica - a Journal of Clinical Medicine;2012, Vol. 7 Issue 2, p148 

    Rheumatoid arthritis (RA) generally affects people between the ages of 20 and 50. Patients with RA have a significantly higher prevalence of the metabolic syndrome (MS) compared to the general population. The increased cardiovascular risk (CVR) associated with RA places this disease among the...

  • Treatment of Obese Diabetic Mice With a Heme 0xygenase Inducer Reduces Visceral and Subcutaneous Adiposity, Increases Adiponectin Levels, and Improves Insulin Sensitivity and Glucose Tolerance. Li, Ming; Kim, Dong Hyun; Tsenovoy, Peter L.; Peterson, Stephen J.; Rezzani, Rita; Rodella, Luigi F.; Aronow, Wilbert S.; Ikehara, Susumu; Abraham, Nader G. // Diabetes;Jun2008, Vol. 57 Issue 6, p1526 

    OBJECTIVE--We hypothesized that the induction of heme oxygenase (HO)-1 and increased HO activity, which induces arterial antioxidative enzymes and vasoprotection in a mouse and a rat model of diabetes, would ameliorate insulin resistance, obesity, and diabetes in the ob mouse model of type 2...

  • There is a smorgasbord of options in the management of dyslipidaemia in visceral obesity. Adis International Limited // Drugs & Therapy Perspectives;Aug2005, Vol. 21 Issue 8, p10 

    Provides information on dyslipidaemia in visceral obesity. Clinical characteristics of the disease; Factors which may increase the risk of cardiovascular disease; Agents which may become useful in correcting insulin resistance and dyslipidaemia in obese patients.

  • Usefulness of combining serum uric acid and high-sensitivity C-reactive protein for risk stratification of patients with metabolic syndrome in community-dwelling women. Kawamoto, Ryuichi; Tabara, Yasuharu; Kohara, Katsuhiko; Miki, Tetsuro; Kusunoki, Tomo; Takayama, Shuzo; Abe, Masanori; Katoh, Tateaki; Ohtsuka, Nobuyuki // Endocrine (1355008X);Aug2013, Vol. 44 Issue 1, p132 

    Metabolic syndrome (MetS) is associated with an increased risk of major cardiovascular events. In women, increased uric acid (UA) levels are associated with MetS and its components. High-sensitivity C-reactive protein (hsCRP) levels are also associated with MetS, and hsCRP levels could be...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics